PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  05/25 04:04:43 pm EDT
53.40 USD   -0.02%
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada has approved Pfizer's COVID-19 oral antiviral treatment - government website

01/17/2022 | 10:10am EDT

Jan 17 (Reuters) - Pfizer Inc:

* CANADA HAS APPROVED PFIZER'S COVID-19 ORAL ANTIVIRAL TREATMENT - GOVERNMENT WEBSITE Source text for Eikon: Further company coverage: (Reporting by David Ljunggren)


© Reuters 2022
All news about PFIZER, INC.
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-..
AQ
10:19aWALL STREET STOCK EXCHANGE : Investors are eagerly awaiting the Fed minutes
10:02aPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ..
BU
08:36aPFIZER INC : Goldman Sachs reiterates its Neutral rating
MD
07:33aPfizer Launches Initiative to Sell Medicines, Vaccines to 45 Low-Income Countries on a ..
MT
06:29aMARKETSCREENER'S WORLD PRESS REVIEW : May 25, 2022
06:00aDavos updates | Zelenskyy says Ukraine won't give up land
AQ
03:37aPfizer to Make Patented Treatments Available at Cost in Lower-Income Countries
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,91x
Yield 2022 3,04%
Capitalization 300 B 300 B -
EV / Sales 2022 2,74x
EV / Sales 2023 3,65x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,41 $
Average target price 57,66 $
Spread / Average Target 7,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-9.55%299 678
JOHNSON & JOHNSON6.04%477 336
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494
NOVO NORDISK A/S1.61%244 637